Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells

Leukemia

Volumn 25, Issue 1, 2011, Pages 89-100

  Kruse, U ^a   Pallasch, C P ^b   Bantscheff, M ^a   Eberhard, D ^a   Frenzel, L ^b   Ghidelli, S ^a   Maier, S K ^a   Werner, T ^a   Wendtner, C M ^b   Drewes, G ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

BMS 387032; chemical proteomics; chronic lymphocytic leukemia; flavopiridol; kinase inhibitors

Indexed keywords

3 [1 (3 AMINOPROPYL) 3 INDOLYL] 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AXITINIB; BOSUTINIB; BRUTON TYROSINE KINASE; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; DOVITINIB; FLAVOPIRIDOL; FLT3 LIGAND; FOSTAMATINIB; GELDANAMYCIN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN KINASE SYK; SORAFENIB; STAUROSPORINE; STEM CELL FACTOR RECEPTOR; SUNITINIB; TYROSINE; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

EID: 78651340521     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.233     Document Type: Article

References (50)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
2. Kumar C, Purandare AV, Lee FY, Lorenzi MV. Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene 2009; 28: 2305-2313.
3. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
4. Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner CM, Hallek M et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008; 112: 1443-1452.
5. Wendtner CM, Eichhorst BF, Hallek MJ. Advances in chemotherapy for chronic lymphocytic leukemia. Semin Hematol 2004; 41: 224-233.
6. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637-2645.
7. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
8. Gaiger A, Heintel D, Jager U. Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia. Eur J Clin Invest 2004; 34 (Suppl 2): 25-30.
9. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25: 1035-1044.
10. Nita-Lazar A, Saito-Benz H, White FM. Quantitative phospho-proteomics by mass spectrometry: past, present, and future. Proteomics 2008; 8: 4433-4443.
11. Sharma K, Weber C, Bairlein M, Greff Z, Keri G, Cox J et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat Methods 2009; 6: 741-744.
12. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008; 4: 691-699.
13. Peters EC, Gray NS. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem Biol 2007; 2: 661-664.
14. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006; 16: 127-136.
15. Pallasch CP, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008; 112: 4213-4219.
16. Bantscheff M, Boesche M, Eberhard D, Matthieson T, Sweetman G, Kuster B. Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer. Mol Cell Proteomics 2008; 7: 1702-1713.
17. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-1169.
18. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
19. Rawstron AC, Bennett F, Hillmen P. The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 724-729.
20. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
21. Gill AL, Verdonk M, Boyle RG, Taylor R. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem 2007; 7: 1408-1422.
22. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics 2004; 3: 490-500.
23. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002; 62: 4244-4255.
24. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005; 12: 621-637.
25. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]-methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004; 47: 1719-1728.
26. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513-2519.
27. Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P et al. Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res 2005; 29: 1347-1352.
28. Essakali S, Carney D, Westerman D, Gambell P, Seymour JF, Dobrovic A. Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail. BMC Biotechnol 2008; 8: 6.
29. Hillmen P. Advancing therapy for chronic lymphocytic leukemia- the role of rituximab. Semin Oncol 2004; 31 (Suppl 2): 22-26.
30. Olaharski AJ, Gonzaludo N, Bitter H, Goldstein D, Kirchner S, Uppal H et al. Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLoS Comput Biol 2009; 5: e1000446.
31. Bres V, Yoh SM, Jones KA. The multi-tasking P-TEFb complex. Curr Opin Cell Biol 2008; 20: 334-340.
32. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007; 16: 92-106.
33. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691-700.
34. Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 2007; 3: 89.
35. Smit LA, Hallaert DY, Spijker R, de GB, Jaspers A, Kater AP et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007; 109: 1660-1668.
36. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115: 369-378.
37. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-13288.
38. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319: 998-1008.
39. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 2009; 114: 1029-1037.
40. Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64: 723-732.
41. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009; 113: 4637-4645.
42. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcrip-tional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008; 29: 302-313.
43. Estable MC, Naghavi MH, Kato H, Xiao H, Qin J, Vahlne A et al. MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein. J Biomed Sci 2002; 9: 234-245.
44. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007; 110: 4445-4454.
45. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833.
46. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37: 429-437.
47. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010; 17: 198-212.
48. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010; 28: 3015-3022.
49. Jones DT, Addison E, North JM, Lowdell MW, Hoffbrand AV, Mehta AB et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood 2004; 103: 1855-1861.
50. Malek SN, Dordai DI, Reim J, Dintzis H, Desiderio S. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7351-7356.